Microcap Ledger Milestone Pharmaceuticals Inc. $MIST
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Montreal, Quebec, Canada
- Fiscal year end
- December 31
- Shares outstanding
- 124,497,980 [10-Q 2026-08-12]
What the company doesAI summary of filing
Milestone Pharmaceuticals is a biopharmaceutical company developing and commercializing cardiovascular medicines. The company's approved product, CARDAMYST (etripamil) nasal spray, is marketed in the United States for converting acute episodes of paroxysmal supraventricular tachycardia (PSVT) to normal heart rhythm in adults and became available in retail pharmacies in the first quarter of 2026. The company is also developing etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR) through a Phase 3 clinical trial and pursuing regulatory approval in other markets including China and the European Union through partnerships. Milestone generates revenue from CARDAMYST sales and funds operations through capital raises, as the company has incurred significant operating losses since inception. [10-K 2026-03-20]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $797.0K | −$54.68M | −$38.77M | $169.73M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | — | −$63.1K | −$49.04M | $73.05M | [DEF 14A 2026-04-30] |
| FY ended Dec 2024 | — | −$41.5K | −$28.85M | $25.31M | [DEF 14A 2026-04-30] |
- Quarterly cash burn
- −$19.38M
- Cash runway Estimate
- ~26.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-12 | 53,327,908 | [10-Q 2024-11-12] |
| 2025-03-13 | 53,353,984 | [10-K 2025-03-13] |
| 2025-05-14 | 53,464,273 | [10-Q 2025-05-14] |
| 2025-08-12 | 84,994,261 | [10-Q 2025-08-12] |
| 2025-11-12 | 85,169,344 | [10-Q 2025-11-12] |
| 2026-03-20 | 117,667,277 | [10-K 2026-03-20] |
| 2026-05-13 | 124,497,980 | [10-Q 2026-05-13] |
| 2026-08-12 | 124,497,980 | [10-Q 2026-08-12] |
- Shelf registration
- S-3 filed 2026-05-13; declared effective 2026-05-22 [S-3 2026-05-13]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-04-16 | Oliveto Joseph | sell | 36,500 | $2.26 | [4 2026-04-20] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-03 | 8-K | Other events |
| 2026-08-12 | 8-K | Results of operations |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-08-07 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-15 | 8-K | Director or officer change; Shareholder vote results |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-13 | S-3 | Registration statement |
| 2026-05-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-13 | 8-K | Results of operations |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-04-30 | DEF 14A | Proxy statement |
| 2026-03-26 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $MIST
Email me when Milestone Pharmaceuticals Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.